Effects of Atomoxetine on Brain Activation During Attention & Reading Tasks in Participants With ADHD & Comorbid Dyslexia
Neurophysiology of Attention-Deficit/Hyperactivity Disorder (ADHD) and Comorbid Dyslexia: Functional Magnetic Resonance Imaging (fMRI) Measures of Brain Activation During Attention and Reading Tasks Pre- and Post-Atomoxetine Treatment
Sponsor: Eli Lilly and Company
This PHASE4 trial investigates Attention Deficit Hyperactivity Disorder and Dyslexia and is currently completed. Eli Lilly and Company leads this study, which shows 10 recorded versions since 2008 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE4
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE4
-
Dec 2022 — Jul 2024 [monthly]
Completed PHASE4
-
Jan 2021 — Dec 2022 [monthly]
Completed PHASE4
-
Mar 2019 — Jan 2021 [monthly]
Completed PHASE4
▶ Show 5 earlier versions
-
Nov 2018 — Mar 2019 [monthly]
Completed PHASE4
-
Jun 2018 — Nov 2018 [monthly]
Completed PHASE4
-
Mar 2018 — Jun 2018 [monthly]
Completed PHASE4
-
Feb 2017 — Mar 2018 [monthly]
Completed PHASE4
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE4
First recorded
Sep 2008
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Eli Lilly and Company
For direct contact, visit the study record on ClinicalTrials.gov .